Ariosa Diagnostics inks deal with LabCorp for prenatal test

Ariosa Diagnostics has signed a deal with LabCorp to bring the startup's Down syndrome-related prenatal blood test to labs around the country. The California company launched the Harmony Prenatal Test earlier this year, and it's designed to detect the genetic condition Trisomy 21, which has been linked to Down syndrome, Forbes reports. The deal with LabCorp will get Ariosa's noninvasive screening into more than 1,000 labs around the U.S., and, at $795 a pop, the test is cheaper than rival Sequenom's $1,900 MaterniT21. Report

Suggested Articles

The AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.